HomeCompareCBLI vs FCPT

CBLI vs FCPT: Dividend Comparison 2026

CBLI yields 63.09% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CBLI wins by $708.2K in total portfolio value
10 years
CBLI
CBLI
● Live price
63.09%
Share price
$3.17
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$757.3K
Annual income
$183,899.77
Full CBLI calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — CBLI vs FCPT

📍 CBLI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCBLIFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CBLI + FCPT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CBLI pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CBLI
Annual income on $10K today (after 15% tax)
$5,362.78/yr
After 10yr DRIP, annual income (after tax)
$156,314.80/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, CBLI beats the other by $151,405.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CBLI + FCPT for your $10,000?

CBLI: 50%FCPT: 50%
100% FCPT50/50100% CBLI
Portfolio after 10yr
$403.2K
Annual income
$94,837.52/yr
Blended yield
23.52%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

CBLI
Analyst Ratings
3
Buy
1
Hold
Consensus: Buy
Altman Z
435.1
Piotroski
1/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CBLI buys
0
FCPT buys
0
No recent congressional trades found for CBLI or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCBLIFCPT
Forward yield63.09%6.05%
Annual dividend / share$2.00$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$757.3K$49.1K
Annual income after 10y$183,899.77$5,775.28
Total dividends collected$633.8K$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: CBLI vs FCPT ($10,000, DRIP)

YearCBLI PortfolioCBLI Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$17,009$6,309.15$11,401$700.92+$5.6KCBLI
2$28,229$10,029.27$13,064$864.84+$15.2KCBLI
3$45,761$15,556.06$15,051$1,072.48+$30.7KCBLI
4$72,532$23,567.66$17,442$1,337.22+$55.1KCBLI
5$112,521$34,911.29$20,340$1,677.08+$92.2KCBLI
6$171,013$50,615.56$23,880$2,116.57+$147.1KCBLI
7$254,878$71,894.60$28,241$2,689.36+$226.6KCBLI
8$372,862$100,142.13$33,660$3,442.07+$339.2KCBLI
9$535,876$136,914.14$40,456$4,439.95+$495.4KCBLI
10$757,287$183,899.77$49,063$5,775.28+$708.2KCBLI

CBLI vs FCPT: Complete Analysis 2026

CBLIStock

Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. The company is headquartered in Buffalo, New York and currently employs 15 full-time employees. The firm is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.

Full CBLI Calculator →

FCPTREIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this CBLI vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CBLI vs SCHDCBLI vs JEPICBLI vs OCBLI vs KOCBLI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.